Association of postpartum oxytocin dose and postpartum bleeding outcomes in nulliparous patients at term

What Was Tested

The paper reports a study of Oxytocin, published as a randomized controlled trial.

Postpartum hemorrhage is a leading cause of morbidity and mortality.

Who Took Part

The abstract describes 2404 women taking part.

PubMed indexes the participants as young adults and adults, women only.

Secondary analysis of a multicenter randomized control trial of 2404 nulliparous women with term singleton pregnancies that investigated immediate vs delayed pushing in women in the second stage of labor (5/2014-12/2017).

How the Study Was Run

The design is described as randomized and multicenter.

Random assignment meant chance, not the researchers, decided who got Oxytocin and who got the comparison, which limits bias.

More than one site took part, so the women came from several places.

The primary outcome was a composite of uterotonic use after initial postpartum oxytocin, any blood transfusion, and postpartum hemorrhage.

Secondary outcomes included individual composite components and select bleeding outcomes.

What Was Measured

PubMed files the paper under topics including Postpartum Hemorrhage, Oxytocin, Oxytocics, Parity and Blood Transfusion.

The authors tagged it with the keywords Pitocin, bleeding, maternal hemorrhage, nulliparous, postpartum oxytocin and term.

What This Means in Plain Language

The paper is a randomized and multicenter study of Oxytocin in 2404 women.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (American journal of obstetrics and gynecology), a journal based in United States.

More context: the Oxytocin compound page, all human trials.